Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 11/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698320 | 1.00 | C3AR1 (0.40) | C3AR1CYP2C19SMN1; SMN2TP53CYP1A2 | |
| SCHEMBL12872151 | 1.00 | C3AR1 (0.40) | C3AR1CYP2C19SMN1; SMN2TP53CYP1A2 | |
| SCHEMBL3693973 | 1.00 | C3AR1 (0.40) | C3AR1CYP2C19SMN1; SMN2TP53CYP1A2 | |
| SCHEMBL1194161 | 0.96 | C3AR1 (0.42) | C3AR1CYP2C19SMN1; SMN2 | |
| SCHEMBL1194163 | 0.96 | C3AR1 (0.42) | C3AR1CYP2C19SMN1; SMN2 | |
| SCHEMBL12872154 | 0.96 | C3AR1 (0.42) | C3AR1CYP2C19SMN1; SMN2 | |
| SCHEMBL3701716 | 0.92 | C3AR1 (0.38) | C3AR1CYP2C19SMN1; SMN2 | |
| SCHEMBL3695567 | 0.92 | C3AR1 (0.38) | C3AR1CYP2C19SMN1; SMN2 | |
| SCHEMBL3700599 | 0.92 | C3AR1 (0.38) | C3AR1CYP2C19SMN1; SMN2 | |
| SCHEMBL3693596 | 0.92 | C3AR1 (0.38) | C3AR1CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | C3AR1 1349/4885CYP2C19 228/4885SMN1; SMN2 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.